创伤患者酒精戒断综合征:苯巴比妥单药与苯二氮䓬类方案的比较
该回顾性队列研究在一家一级创伤中心纳入411例有酒精戒断综合征风险的创伤患者,118例接受苯二氮䓬类方案、293例接受低剂量口服苯巴比妥方案。苯巴比妥组发生复杂戒断(癫痫发作或酒精戒断性谵妄/震颤谵妄)的比值比与苯二氮䓬组相比无统计学显著差异(OR 0.52,95%CI 0.21-1.39);但苯巴比妥组发生无并发症戒断的比值更低(OR 0.08,95%CI 0.04-0.14),需要升级治疗的比值更低(OR 0.45,95%CI 0.24-0.84),住院时间较苯二氮䓬组缩短3.1天(p=0.002)。ICU无事件天数、无呼吸机天数、无谵妄天数两组无差异。作者认为,苯巴比妥方案是创伤患者酒精戒断综合征管理中安全有效的替代方案。
要点
- 在创伤酒精戒断综合征患者中,苯巴比妥组发生复杂戒断(癫痫发作或酒精戒断性谵妄/震颤谵妄)的OR为0.52(95%CI 0.21-1.39),与苯二氮䓬组相比未达统计学显著。
- 苯巴比妥组发生无并发症戒断的OR为0.08(95%CI 0.04-0.14),需要升级治疗的OR为0.45(95%CI 0.24-0.84),均低于苯二氮䓬组。
- 苯巴比妥组住院时间较苯二氮䓬组缩短3.1天(p=0.002)。
- 两组在ICU无事件天数、无呼吸机天数、无谵妄天数方面无差异。
- 作者认为,苯巴比妥方案是创伤患者酒精戒断综合征管理中安全有效的替代方案(证据等级:治疗/管理,Level IV)。
适用人群与场景
- 在一家一级创伤中心接受治疗、有酒精戒断综合征风险的创伤患者。
- 排除入院前正在使用苯二氮䓬类或巴比妥类药物的患者。
- 排除在研究药物启动前接受丙泊酚或右美托咪定的患者。
- 排除就诊时已出现震颤谵妄或癫痫发作的患者。
- 排除就诊后24小时内死亡或出院的患者。
处置流程与药物剂量
- 苯二氮䓬类方案:按该中心苯二氮䓬类方案管理酒精戒断综合征。
- 苯巴比妥方案:低剂量口服苯巴比妥方案。
研究设计与关键结果
- 研究类型:回顾性队列研究,单家一级创伤中心,共411例患者,其中118例接受苯二氮䓬类方案、293例接受苯巴比妥方案。
- 主要终点:苯巴比妥组与苯二氮䓬组相比,发生复杂戒断(癫痫发作或酒精戒断性谵妄/震颤谵妄)的OR为0.52(95%CI 0.21-1.39),未达统计学显著。
- 次要终点:苯巴比妥组发生无并发症戒断的OR为0.08(95%CI 0.04-0.14),需要升级治疗的OR为0.45(95%CI 0.24-0.84)。
- 苯巴比妥组住院时间较苯二氮䓬组缩短3.1天(p=0.002)。
- 两组在ICU无事件天数、无呼吸机天数、无谵妄天数方面无差异。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 证据等级:治疗/管理,Level IV。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于苯巴比妥的方案是创伤患者酒精戒断综合征管理中安全有效的替代方案,可考虑用于有酒精戒断综合征风险的创伤患者。
- 适用人群为有酒精戒断综合征风险的创伤患者,但不包括入院前使用苯二氮䓬类或巴比妥类药物、研究药物启动前使用丙泊酚或右美托咪定、就诊时已出现震颤谵妄或癫痫发作、以及就诊后24小时内死亡或出院的患者。
- 苯巴比妥组住院时间较苯二氮䓬组缩短3.1天(p=0.002),但两组ICU无事件天数、无呼吸机天数、无谵妄天数无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Alcohol withdrawal syndrome (AWS) is associated with increased morbidity and mortality in the trauma population. Benzodiazepines (BZDs) are standard of care for AWS; however, given the risk of delirium with BZDs and reports of BZD-refractory withdrawal, phenobarbital (PHB) has emerged as an alternative therapy for AWS. Safety and efficacy studies of PHB for AWS in trauma patients are lacking. Our aim was to compare a BZD versus PHB protocol in the management of AWS in trauma patients.
METHODS: We performed a retrospective cohort study at a level 1 trauma center of patients at risk for AWS managed with either a BZD or a low-dose oral PHB regimen. Patients were excluded if they were taking BZDs or barbiturates before admission, received propofol or dexmedetomidine before initiation of the study drug, presented with delirium tremens or seizures, or died or discharged within 24 hours of presentation. The primary outcome was complicated AWS (seizures or alcohol withdrawal delirium/delirium tremens). Secondary outcomes included uncomplicated AWS; therapy escalation; oversedation; delirium-, intensive care unit-, and ventilator-free days; and length of stay.
RESULTS: A total of 411 patients were identified; 118 received BZD, and 293 received PHB. The odds of developing complicated AWS with PHB versus BZD-based therapy were not statistically significant (odds ratio [OR], 0.52; 95% confidence interval [CI], 0.21-1.39); however, patients receiving PHB were less likely to develop uncomplicated AWS (OR, 0.08; 95% CI, 0.04-0.14) and less likely to require escalation of therapy (OR, 0.45; 95% CI, 0.24-0.84). The PHB group had a length of stay 3.1 days shorter than the BZD group ( p = 0.002). There was no difference in intensive care unit-, ventilator-, or delirium-free days.
CONCLUSION: A PHB-based protocol for the management of AWS is a safe and effective alternative to BZD-based regimens in trauma patients.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.
参考来源
- Fleenor LM, Beavers JR, Tidwell WP, et al. Comparison of phenobarbital monotherapy to a benzodiazepine-based regimen for management of alcohol withdrawal syndrome in trauma patients. J Trauma Acute Care Surg. 2023. PMID: 37599414. doi:10.1097/TA.0000000000004116
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。